Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734628071.793582410 ◽

2021 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

The Lancet ◽

10.1016/s0140-6736(15)60027-7 ◽

2015 ◽

Vol 385 (9980) ◽

pp. 1873-1883 ◽

Cited By ~ 227

Author(s):

Peter Hillmen ◽

Tadeusz Robak ◽

Ann Janssens ◽

K Govind Babu ◽

Janusz Kloczko ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3 ◽

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30788-5 ◽

2019 ◽

Vol 20 (1) ◽

pp. 43-56 ◽

Cited By ~ 158

Author(s):

Carol Moreno ◽

Richard Greil ◽

Fatih Demirkan ◽

Alessandra Tedeschi ◽

Bertrand Anz ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793562618 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Previously Treated

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3335059 ◽

2019 ◽

Author(s):

Paula Cramer ◽

Julia V. Tresckow ◽

Sandra Robrecht ◽

Jasmin Bahlo ◽

Moritz Fürstenau ◽

...

Keyword(s):

Phase Ii ◽

Primary Endpoint ◽

Lymphocytic Leukaemia ◽

Phase Ii Trial ◽

Open Label ◽

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(18)30030-9 ◽

2018 ◽

Vol 5 (4) ◽

pp. e170-e180 ◽

Cited By ~ 20

Author(s):

Jennifer R Brown ◽

Mehdi Hamadani ◽

John Hayslip ◽

Ann Janssens ◽

Nina Wagner-Johnston ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Phase 2 Trial ◽

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30051-1 ◽

2016 ◽

Vol 17 (7) ◽

pp. 928-942 ◽

Cited By ~ 285

Author(s):

Barbara Eichhorst ◽

Anna-Maria Fink ◽

Jasmin Bahlo ◽

Raymonde Busch ◽

Gabor Kovacs ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

First Line ◽

Open Label ◽

Phase 3

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356653.793538193 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793538186 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Previously Treated

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00143-6 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1370-1379 ◽

Cited By ~ 72

Author(s):

Marinus H J van Oers ◽

Kazimierz Kuliczkowski ◽

Lukáš Smolej ◽

Mario Petrini ◽

Fritz Offner ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3